Literature DB >> 17308059

17-Allylamino-17-demethoxygeldanamycin enhances the lethality of deoxycholic acid in primary rodent hepatocytes and established cell lines.

Clint Mitchell1, Margaret A Park, Guo Zhang, Song Iy Han, Hisashi Harada, Richard A Franklin, Adly Yacoub, Pin-Lan Li, Philip B Hylemon, Steven Grant, Paul Dent.   

Abstract

Ansamycin antibiotics that target heat shock protein 90 function are being developed as anticancer agents but are also known to be dose limiting in patients due to hepatotoxicity. Herein, to better understand how the normal tissue toxicity of geldanamycins could be ameliorated to improve the therapeutic index of these agents, we examined the interactions of 17-allylamino-17-demethoxygeldanamycin (17AAG) and the secondary bile acid deoxycholic acid (DCA) in hepatocytes and fibroblasts. DCA and 17AAG interacted in a greater than additive fashion to cause hepatocyte cell death within 2 to 6 h of coadministration. As single agents DCA, but not 17AAG, enhanced the activity of extracellular signal-regulated kinase 1/2, AKT, c-Jun NH(2)-terminal kinase 1/2 (JNK1/2), and p38 mitogen-activated protein kinase (MAPK). Combined exposure of cells to DCA and 17AAG further enhanced JNK1/2 and p38 MAPK activity. Inhibition of JNK1/2 or p38 MAPK, but not activator protein-1, suppressed the lethality of 17AAG and of 17AAG and DCA. Constitutive activation of AKT, but not MAPK/extracellular signal-regulated kinase kinase 1/2, suppressed 17AAG- and DCA-induced cell killing and reduced activation of JNK1/2. DCA and 17AAG exposure promoted association of BAX with mitochondria, and functional inhibition of BAX or caspase-9, but not of BID and caspase-8, suppressed 17AAG and DCA lethality. DCA and 17AAG interacted in a greater than additive fashion to promote and prolong the generation of reactive oxygen species (ROS). ROS-quenching agents, inhibition of mitochondrial function, expression of dominant-negative thioredoxin reductase, or expression of dominant-negative apoptosis signaling kinase 1 suppressed JNK1/2 and p38 MAPK activation and reduced cell killing after 17AAG and DCA exposure. The potentiation of DCA-induced ROS production by 17AAG was abolished by Ca(2+) chelation and ROS generation, and cell killing following 17AAG and DCA treatment was abolished in cells lacking expression of PKR-like endoplasmic reticulum kinase. Thus, DCA and 17AAG interact to stimulate Ca(2+)-dependent and PKR-like endoplasmic reticulum kinase-dependent ROS production; high levels of ROS promote intense activation of the p38 MAPK and JNK1/2 pathways that signal to activate the intrinsic apoptosis pathway.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17308059     DOI: 10.1158/1535-7163.MCT-06-0532

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  14 in total

1.  17-allylamino-17-demethoxygeldanamycin and MEK1/2 inhibitors kill GI tumor cells via Ca2+-dependent suppression of GRP78/BiP and induction of ceramide and reactive oxygen species.

Authors:  Teneille Walker; Clint Mitchell; Margaret A Park; Adly Yacoub; Mohamed Rahmani; Dieter Häussinger; Roland Reinehr; Christina Voelkel-Johnson; Paul B Fisher; Steven Grant; Paul Dent
Journal:  Mol Cancer Ther       Date:  2010-05-04       Impact factor: 6.261

2.  Mitogen-activated protein kinase kinase 1/2 inhibitors and 17-allylamino-17-demethoxygeldanamycin synergize to kill human gastrointestinal tumor cells in vitro via suppression of c-FLIP-s levels and activation of CD95.

Authors:  Margaret A Park; Guo Zhang; Clint Mitchell; Mohamed Rahmani; Hossein Hamed; Michael P Hagan; Adly Yacoub; David T Curiel; Paul B Fisher; Steven Grant; Paul Dent
Journal:  Mol Cancer Ther       Date:  2008-09       Impact factor: 6.261

3.  Sorafenib activates CD95 and promotes autophagy and cell death via Src family kinases in gastrointestinal tumor cells.

Authors:  Margaret A Park; Roland Reinehr; Dieter Häussinger; Christina Voelkel-Johnson; Besim Ogretmen; Adly Yacoub; Steven Grant; Paul Dent
Journal:  Mol Cancer Ther       Date:  2010-08-03       Impact factor: 6.261

4.  A serotype 5/3 adenovirus expressing MDA-7/IL-24 infects renal carcinoma cells and promotes toxicity of agents that increase ROS and ceramide levels.

Authors:  Margaret A Park; Hossein A Hamed; Clint Mitchell; Nichola Cruickshanks; Rupesh Dash; Jeremy Allegood; Igor P Dmitriev; Gary Tye; Besim Ogretmen; Sarah Spiegel; Adly Yacoub; Steven Grant; David T Curiel; Paul B Fisher; Paul Dent
Journal:  Mol Pharmacol       Date:  2010-11-30       Impact factor: 4.436

5.  cAMP-guanine exchange factor protection from bile acid-induced hepatocyte apoptosis involves glycogen synthase kinase regulation of c-Jun NH2-terminal kinase.

Authors:  A Johnston; K Ponzetti; M S Anwer; C R L Webster
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2011-05-05       Impact factor: 4.052

6.  Oxidative stress plays a critical role in inactivating mutant BRAF by geldanamycin derivatives.

Authors:  Yayoi Fukuyo; Masahiro Inoue; Takuma Nakajima; Ryuji Higashikubo; Nobuko T Horikoshi; Clayton Hunt; Anny Usheva; Michael L Freeman; Nobuo Horikoshi
Journal:  Cancer Res       Date:  2008-08-01       Impact factor: 12.701

7.  Vorinostat and sorafenib increase ER stress, autophagy and apoptosis via ceramide-dependent CD95 and PERK activation.

Authors:  Margaret A Park; Guo Zhang; Aditi Pandya Martin; Hossein Hamed; Clint Mitchell; Philip B Hylemon; Martin Graf; Mohamed Rahmani; Kevin Ryan; Xiang Liu; Sarah Spiegel; James Norris; Paul B Fisher; Steven Grant; Paul Dent
Journal:  Cancer Biol Ther       Date:  2008-10-12       Impact factor: 4.742

8.  Vorinostat and sorafenib synergistically kill tumor cells via FLIP suppression and CD95 activation.

Authors:  Guo Zhang; Margaret A Park; Clint Mitchell; Hossein Hamed; Mohamed Rahmani; Aditi Pandya Martin; David T Curiel; Adly Yacoub; Martin Graf; Ray Lee; John D Roberts; Paul B Fisher; Steven Grant; Paul Dent
Journal:  Clin Cancer Res       Date:  2008-09-01       Impact factor: 12.531

9.  Sorafenib and vorinostat kill colon cancer cells by CD95-dependent and -independent mechanisms.

Authors:  Teneille Walker; Clint Mitchell; Margaret A Park; Adly Yacoub; Martin Graf; Mohamed Rahmani; Peter J Houghton; Christina Voelkel-Johnson; Steven Grant; Paul Dent
Journal:  Mol Pharmacol       Date:  2009-05-29       Impact factor: 4.436

10.  BCL-2 family inhibitors enhance histone deacetylase inhibitor and sorafenib lethality via autophagy and overcome blockade of the extrinsic pathway to facilitate killing.

Authors:  Aditi Pandya Martin; Margaret A Park; Clint Mitchell; Teneille Walker; Mohamed Rahmani; Andrew Thorburn; Dieter Häussinger; Roland Reinehr; Steven Grant; Paul Dent
Journal:  Mol Pharmacol       Date:  2009-05-29       Impact factor: 4.436

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.